Original Query: "myoclonic epilepsy myopathy sensory ataxia" OR "Mitochondrial Diseases"
Previous Study | Return to List | Next Study

RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00060515
Recruitment Status : Terminated
First Posted : May 8, 2003
Last Update Posted : August 5, 2005
Information provided by:
Repligen Corporation

Brief Summary:
The objective of the study is to determine the safety and tolerability of RG2133 in patients with Mitochondrial Disease.

Condition or disease Intervention/treatment Phase
Mitochondrial Diseases Drug: RG2133 (2',3',5'-tri-O-acetyluridine) Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: Non-Randomized
Primary Purpose: Treatment
Official Title: An Open-Label Dose-Escalation Phase I Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RG2133 (2',3',5'-Tri-O-Acetyluridine) in the Treatment of Inherited Mitochondrial Diseases

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   3 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Mitochondrial Disease Identifier: NCT00060515     History of Changes
Other Study ID Numbers: RG2133-01
First Posted: May 8, 2003    Key Record Dates
Last Update Posted: August 5, 2005
Last Verified: August 2005

Additional relevant MeSH terms:
Mitochondrial Diseases
Metabolic Diseases